Ag5
Solid Tumors
Pre-clinicalActive
Key Facts
About Arjuna Therapeutics
Arjuna Therapeutics is a private, pre-clinical biotech pioneering a new therapeutic approach based on Nobel Laureate James D. Watson's hypothesis that reducing antioxidant levels is key to treating late-stage cancer. Its core innovation is the Therapeutic Molecular Clusters (TMCs) platform, which creates catalytic small molecules, with lead candidate Ag5 targeting a known cancer Achilles' heel. The company is pre-revenue and focused on advancing its first-in-class antioxidant deactivator through development, aiming to address a significant unmet need in advanced solid tumors. Its vision is to remove the fear of a cancer diagnosis by making cancer survivable.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |